Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
Autor: | Cornelius Knabbe, Udo Boeken, Rasmus Rivinius, Benjamin Müller, Angelika Costard-Jäckle, Zdenek Provaznik, René Schramm, Bastian Fischer, Assad Haneya, Jan Gummert |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Male T-Lymphocytes Booster dose BioNTech/Pfizer (BNT162b2) vaccine Antibodies Viral Covid-19 infection Organ transplantation 0302 clinical medicine Immunogenicity Vaccine 030212 general & internal medicine Immunity Cellular biology Immunogenicity Vaccination General Medicine Middle Aged Cardiology Immunocompromised patients Female Antibody Cardiology and Cardiovascular Medicine Immunosuppressive Agents Lung Transplantation Adult medicine.medical_specialty COVID-19 Vaccines Adolescent Heart-Lung Transplantation QuantiFERON 03 medical and health sciences Immunocompromised Host Young Adult Immune system Internal medicine medicine Humans Seroconversion BNT162 Vaccine Immunization Schedule Aged Transplant recipients Original Paper business.industry COVID-19 Antibodies Neutralizing Immunity Humoral 030104 developmental biology Case-Control Studies Immunology biology.protein Heart Transplantation business |
Zdroj: | Clinical Research in Cardiology |
ISSN: | 1861-0692 1861-0684 |
Popis: | Aims Immunocompromised patients have been excluded from studies of SARS-CoV-2 messenger RNA vaccines. The immune response to vaccines against other infectious agents has been shown to be blunted in such patients. We aimed to analyse the humoral and cellular response to prime-boost vaccination with the BNT162b2 vaccine (Pfizer-BioNTech) in cardiothoracic transplant recipients. Methods and results A total of 50 transplant patients [1–3 years post heart (42), lung (7), or heart–lung (1) transplant, mean age 55 ± 10 years] and a control group of 50 healthy staff members were included. Blood samples were analysed 21 days after the prime and the boosting dose, respectively, to quantify anti-SARS-CoV-2 spike protein (S) immunoglobulin titres (tested by Abbott, Euroimmun and RocheElecsys Immunoassays, each) and the functional inhibitory capacity of neutralizing antibodies (Genscript). To test for a specific T-cell response, heparinized whole blood was stimulated with SARS-CoV-2 specific peptides, covering domains of the viral spike, nucleocapsid and membrane protein, and the interferon-γ release was measured (QuantiFERON Monitor ELISA, Qiagen). The vast majority of transplant patients (90%) showed neither a detectable humoral nor a T-cell response three weeks after the completed two-dose BNT162b2 vaccination; these results are in sharp contrast to the robust immunogenicity seen in the control group: 98% exhibited seroconversion after the prime dose already, with a further significant increase of IgG titres after the booster dose (average > tenfold increase), a more than 90% inhibition capability of neutralizing antibodies as well as evidence of a T-cell responsiveness. Conclusions The findings of poor immune responses to a two-dose BNT162b2 vaccination in cardiothoracic transplant patients have a significant impact for organ transplant recipients specifically and possibly for immunocompromised patients in general. It urges for a review of future vaccine strategies in these patients. |
Databáze: | OpenAIRE |
Externí odkaz: |